Pharmacological treatment of lower urinary tract dysfunction.
D000317:Adrenergic alpha-Antagonists / Q000378:metabolism; D000319:Adrenergic beta-Antagonists / Q000378:metabolism; D000588:Amines / Q000627:therapeutic use; D006145:Guanethidine / Q000627:therapeutic use; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008297:Male; D010276:Parasympatholytics / Q000627:therapeutic use; D010277:Parasympathomimetics / Q000378:metabolism; D014521:Urethra / Q000294:innervation; D001743:Urinary Bladder / Q000294:innervation; D014549:Urinary Incontinence / Q000188:drug therapy* / Q000378:metabolism; D014551:Urinary Tract / Q000294:innervation
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000588:Amines; D010276:Parasympatholytics; D010277:Parasympathomimetics; D007099:Imipramine; D006145:Guanethidine